リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Polypharmacy and Clinical Outcomes in Hospitalized Patients With Acute Decompensated Heart Failure」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Polypharmacy and Clinical Outcomes in Hospitalized Patients With Acute Decompensated Heart Failure

Ozasa, Neiko Kato, Takao Morimoto, Takeshi Yaku, Hidenori Yamamoto, Erika Inuzuka, Yasutaka Tamaki, Yodo Kitai, Takeshi Washida, Koichi Seko, Yuta Yoshikawa, Yusuke Sato, Yukihito Motoki, Hirohiko Kuwahara, Koichiro Kimura, Takeshi 京都大学 DOI:10.1097/JCN.0000000000000885

2023.01

概要

BACKGROUND: Polypharmacy is a common problem among patients with acute decompensated heart failure (ADHF) who often have multiple comorbidities. OBJECTIVE: The aim of this study was to define the number of medications at hospital discharge and whether it is associated with clinical outcomes at 1 year.

METHODS: We evaluated the number of medications in 2578 patients with ADHF who were ambulatory at hospital discharge in the Kyoto Congestive Heart Failure Registry and compared 1-year outcomes in 4 groups categorized by quartiles of the number of medications (quartile 1, ≤ 5; quartile 2, 6-8; quartile 3, 9-11; and quartile 4, ≥ 12).

RESULTS: At hospital discharge, the median number of medications was 8 (interquartile range, 6-11) with 81.5% and 27.8% taking more than 5 and more than 10 medications, respectively. The cumulative 1-year incidence of a composite of death or rehospitalization (primary outcome measure) increased incrementally with an increasing number of medications (quartile 1, 30.8%; quartile 2, 31.6%; quartile 3, 39.7%; quartile 4, 50.3%; P < .0001). After adjusting for confounders, the excess risks of quartile 4 relative to those of quartile 1 remained significant (P = .01).

CONCLUSIONS: In the contemporary cohort of patients with ADHF in Japan, polypharmacy at hospital discharge was common, and excessive polypharmacy was associated with a higher risk of mortality and rehospitalizations within a 1-year period. Collaborative disease management programs that include a careful review of medication lists and an appropriate deprescribing protocol should be implemented for these patients.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–724.

2. Leendertse AJ, Egberts AC, Stoker LJ, Van Den Bemt PM. Frequency of and risk factors for preventable medicationrelated hospital admissions in the Netherlands. Arch Intern Med. 2008;168:1890–1896.

3. Gheorghiade M, Shah AN, Vaduganathan M, et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes. Academics', clinicians', industry's, regulators', and payers' perspectives. Heart Fail Clin. 2013;9:285–290.

4. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119:3028–3035.

5. Writing Committee MembersYancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association task force on practice guidelines. Circulation. 2013;128:e240–e327.

6. Baron-Franco B, McLean G, Mair F, et al. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e314–e320.

7. Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352–360.

8. Yaku H, Ozasa N, Morimoto T, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan: observations from the prospective, multicenter Kyoto Congestive Heart Failure (KCHF) registry. Circ J. 2018;82:2811–2819.

9. Yamamoto E, Kato T, Ozasa N, et al. Kyoto Congestive Heart Failure (KCHF) study: rationale and design. ESC Heart Fail. 2017;4:216–223.

10. Ito-Ihara T. Outline of ethical guidelines for medical and health research involving human subjects. Jpn Pharmacol Ther. 2015;43:s11–s21.

11. World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC). 2021. Available at: https:// www.whocc.no/atc_ddd_index/.

12. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136–143.

13. Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74.

14. Wehling M. How to use the FORTA (“Fit fOR The Aged”) list to improve pharmacotherapy in the elderly. Drug Res (Stuttg). 2016;66:57–62.

15. Friedmann E, Thomas SA, Liu F, et al. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J. 2006;152:940.e1–940.e948.

16. Schiøtz ML, Frølich A, Jensen AK, et al. Polypharmacy and medication deprescribing: a survey among multimorbid older adults in Denmark. Pharmacol Res Perspect. 2018;6:e00431.

17. Achterhof AB, Rozsnyai Z, Reeve E, et al. Potentially inappropriate medication and attitudes of older adults towards deprescribing. PLoS One. 2020;15:e0240463.

18. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–834.

19. Maddox TM, Albert NM, Borden WB, et al. The learning healthcare system and cardiovascular care: a scientific statement from the American Heart Association. Circulation. 2017;135:e826–e857.

20. Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. BMJ. 2015;351:h5000.

21. Kamiya K, Yamamoto T, Tsuchihashi-Makaya M, et al. Nationwide survey of multidisciplinary care and cardiac rehabilitation for patients with heart failure in Japan—an analysis of the AMED-CHF study. Circ J. 2019;83:1546–1552.

22. Mahé I, Sterpu R, Bertoletti L, et al. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices? PLoS One. 2015;10:e0128741.

23. Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13:e006977.

24. Kripalani S, Roumie CL, Dalal AK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med. 2012;157:1–10.

25. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. Am Fam Physician. 2013;87:331–336.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る